Comparative Pharmacology
Head-to-head clinical analysis: AMIDATE versus DESFLURANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMIDATE versus DESFLURANE.
AMIDATE vs DESFLURANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Desflurane is a volatile general anesthetic that potentiates inhibitory GABA and glycine neurotransmission and inhibits excitatory NMDA glutamate receptors, leading to neuronal hyperpolarization and reduced neuronal excitability.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Induction: 3-12% inhaled, titrated to effect; maintenance: 2-6% inhaled, adjusted to maintain adequate anesthetic depth with up to 1 MAC (6.0% at 37°C, 1 atm).
None Documented
None Documented
Clinical Note
moderateDesflurane + Torasemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide."
Clinical Note
moderateDesflurane + Etacrynic acid
"The risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid."
Clinical Note
moderateDesflurane + Furosemide
"The risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide."
Clinical Note
moderateDesflurane + Bumetanide
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Terminal elimination half-life is 3.5–4.5 minutes (context-sensitive half-life after prolonged anesthesia can be longer due to distribution, but true elimination is rapid due to low blood/gas partition coefficient).
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Primarily eliminated via exhalation; minimal hepatic metabolism (<0.02%). Renal excretion of metabolites negligible. >99% excreted unchanged by lungs.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Desflurane is combined with Bumetanide."